Daratumumab

Overview

Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.[1][2][3] WP

Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma. It was granted orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.[4] WP

It is available in combination with hyaluronidase as daratumumab/hyaluronidase (brand name Darzalex Faspro).[5][6] WP

Uses, dosage and effects

Medical uses

In May 2018, the US Food and Drug Administration (FDA) approved daratumumab for use in combination with bortezomib (also termed Velcade), melphalan and prednisone to include the treatment of people with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant.[7] WP

In the European Union it is indicated as monotherapy for the treatment of adults with relapsed and refractory multiple myeloma whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.[8][9] WP

Results of the recently completed ALCYONE 7-year study were published in 2025. This study compared 350 newly diagnosed multiple myeloma patients treated with the standard Velcade, melphalan, and prednisone, i.e., VMP, regimen versus 356 newly diagnosed multiple myeloma patients treated with VMP plus Darzalex, i.e., D-VMP, regimen. All patients were ineligible for autologous stem cell transplantation. During the 9 cycles of treating patients with VMP, D-VMP patients also received intravenous injections of Darzalex (16 mg/kilogram body weight) once weekly in cycle 1, once every 3 weeks in cycles 2-9, and once every 4 weeks thereafter until a patient developed unacceptable toxicity or disease progression or when the study was ended after an average of 86.7 months. The median overall survival time (i.e., time when 50% of the patients were still alive) was 83.0 months for D-MVP patients compared to 53.6 months for VMP patients (p<000.1). There were no significant differences in the adverse responses of the two groups with respect to their development of treatment-related neutropenia, thrombocytopenia, anemia, or other serious adverse drug-related responses. D-VMP-treated patients often had minimal residual disease whereas VMP-treated patients more often had more extensive disease, i.e., D-VMP patients had less disease as defined by having fewer malignant plasma cells in their bone marrow than VMP patients. In another study, the MIAI study published in 2022 reported similar findings, e.g., the addition of Darzalex to treating autologous stem cell transplant-ineligible multiple myeloma patients with lenalidomide plus dexamethasone significantly improved their responses.[10][11] WP

Risks and side effects

Side effects

Treatment of multiple myeloma with daratumumab potentially increases the patient's susceptibility to bacterial and viral infections, due to the killing of natural killer cells (which are the main innate immune system defense against virus). Daratumumab frequently causes human cytomegalovirus (CMV) reactivation by an unknown mechanism. Injection related reactions (inflammation-like) are also common.[12][13][14] WP

Interactions

With blood compatibility testing

Daratumumab can also bind to CD38 present on red blood cells and interfere with routine testing for clinically significant antibodies. People will show a panel-reactive antibody response, including a positive auto-control, which tends to mask the presence of any clinically significant antibodies. Treatment of the antibody panel cells with dithiothreitol (DTT) and repeating testing will effectively negate the binding of daratumumab to CD38 on the red blood cell surface; however, DTT also inactivates/destroys many antigens on the red blood cell surface by disrupting disulfide bonds. The only antigen system affected that is associated with common, clinically significant antibodies is Kell, making crossmatch testing with K-negative RBCs a reasonable alternative when urgent transfusion is indicated. It is therefore advisable to do a baseline antibody screen and Rh & Kell phenotyping (type and screen) before starting the therapy. If antibody screen is negative, proceed with phenotype matched transfusions during therapy. If antibody screen is positive, give specific antigen negative blood. The incompatibility may persist for up to 6 months after stopping the medicine. Furthermore, blood transfusion centers should be routinely notified when sending such a sample.[15] WP

With flow cytometry testing

Daratumumab can also interfere with flow cytometric evaluation of multiple myeloma, causing an apparent lack of plasma cells.[16] WP

Pharmacology

Mechanism of action

Daratumumab is an IgG1k monoclonal antibody directed against CD38. CD38 is overexpressed in multiple myeloma cells. Daratumumab binds to a different CD38 epitope amino-acid sequence than does the anti-CD38 monoclonal antibody isatuximab. Daratumumab binds to CD38, causing cells to apoptose via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, inhibition of mitochondrial transfer or antibody-dependent cellular phagocytosis.[17–21] WP

These effects are dependent upon fragment crystallizable region immune effector mechanisms. Antibody-dependent cellular cytotoxicity is by means of natural killer cells.[22][23] WP

Unlike isatuximab which causes apoptosis directly, daratumumab only induces apoptosis indirectly.[22] WP

Multiple myeloma cells with higher levels of CD38 show greater daratumumab-mediated cell lysis than cells with low CD38 expression. CD38 enzyme results in the formation of the immunosuppressive substance adenosine, so eliminating CD38-containing cells increases the ability of the immune system to eliminate cancer.[18][24] WP

History

History

Encouraging preliminary results were reported in June 2012, from a Phase I/II clinical trial in relapsed multiple myeloma participants. Updated trial results presented in December 2012, indicate daratumumab is continuing to show promising single-agent anti-myeloma activity. A 2015 study compared monotherapy 8 and 16 mg/kg at monthly to weekly intervals.[2][25][26] WP

Daratumumab was given priority review status by the US Food and Drug Administration (FDA) for multiple myeloma as a combination therapy (second line).[20] WP

Daratumumab phase III trials for multiple myeloma show great promise in combination therapy with lenalidomide and dexamethasone, as well as with bortezomib and dexamethasone.[27][28] WP

In November 2015, the US Food and Drug Administration (FDA) approved daratumumab for treatment of multiple myeloma in people who had received at least three prior therapies. In May 2016 daratumumab was also conditionally approved by the European Medicines Agency for treatment of multiple myeloma.[29][30][31] WP

In November 2016, the FDA approved daratumumab in combination with lenalidomide or bortezomib and dexamethasone for the treatment of people with multiple myeloma who have received at least one prior therapy.[32] WP

The European Commission granted a marketing authorization in May 2016.[33] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101. WHO Drug Information. 2009
2. Journal / agency Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. The New England Journal of Medicine. September 2015. doi:10.1056/NEJMoa1506348 · PMID 26308596
3. Other Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
4. Other Daratumumab Receives Breakthrough Therapy Designation from US Food and Drug Administration. 1 May 2013
5. Journal / agency FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma. 1 May 2020
6. Other Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, Darzalex Faspro (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma. 1 May 2020
7. Other FDA approves Darzalex for newly diagnosed, transplant-ineligible multiple myeloma
8. Journal / agency Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, Rosinol L, Minnema M, Teipel R, van Doesum J, Hänel M, Lenain P, Botella-Garcia C, Koenecke C, Ducastelle S, Sanz J, Schroyens W, Zuckerman T, Monaco F, Koster L, de Wreede L, Hayden PJ, Schönland S, Yakoub-Agha I, Beksac M. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT. Bone Marrow Transplantation. March 2022. doi:10.1038/s41409-021-01560-y · PMID 35013536
9. Journal / agency SUMMARY OF PRODUCT CHARACTERISTICS
10. Journal / agency Mateos MV, San-Miguel J, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Yoon SS, Iosava G, Fujisaki T, Garg M, Ngo M, Katz EG, Krevvata M, Bolyard K, Carson R, Borgsten F, Dimopoulos MA. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. The Lancet. Oncology. May 2025. doi:10.1016/S1470-2045(25)00018-X · PMID 40220771
11. Journal / agency San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, Mateos MV, Touzeau C, Jakubowiak A, Usmani SZ, Cook G, Cavo M, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJ. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. January 2022. doi:10.1182/blood.2020010439 · PMID 34269818 · PMC8796656
12. Journal / agency Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, Ljungman P, Wagner AK, Alici E. Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLOS ONE. 2019. doi:10.1371/journal.pone.0211927 · PMID 30759167 · PMC6374018
13. Journal / agency Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, Saito K, Ichikawa S, Fujiwara T, Fukuhara N, Harigae H. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. Annals of Hematology. August 2019. doi:10.1007/s00277-019-03645-7 · PMID 30824957
14. Journal / agency Jain A, Ramasamy K. Evolving Role of Daratumumab: From Backbencher to Frontline Agent. Clinical Lymphoma, Myeloma & Leukemia. September 2020. doi:10.1016/j.clml.2020.03.010 · PMID 32331971
15. Journal / agency Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, Doshi P, Kaufman RM. Resolving the daratumumab interference with blood compatibility testing. Transfusion. June 2015. doi:10.1111/trf.13069 · PMID 25764134
16. Journal / agency Perincheri S, Torres R, Tormey CA, Smith BR, Rinder HM, Siddon AJ. Daratumumab Interferes with Flow Cytometric Evaluation of Multiple Myeloma. Blood. 2 December 2016. doi:10.1182/blood.V128.22.5630.5630
17. Journal / agency Dhillon S. Isatuximab: First Approval. Drugs. June 2020. doi:10.1007/s40265-020-01311-1 · PMID 32347476
18. Journal / agency Konen JM, Fradette JJ, Gibbons DL. The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors. Cells. December 2019. doi:10.3390/cells9010052 · PMID 31878283 · PMC7016859
19. Journal / agency Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, Barreca A, Malavasi F, Baldovino S. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond. International Journal of Molecular Sciences. June 2020. doi:10.3390/ijms21114129 · PMID 32531894 · PMC7312896
20. Journal / agency Daratumumab - Janssen Biotech - AdisInsight
21. Journal / agency Mistry JJ, Moore JA, Kumar P, Marlein CR, Hellmich C, Pillinger G, Jibril A, Di Palma F, Collins A, Bowles KM, Rushworth SA. Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells. Haematologica. February 2021. doi:10.3324/haematol.2019.242974 · PMID 32193250 · PMC7849566
22. Journal / agency Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells. November 2019. doi:10.3390/cells8121522 · PMID 31779273 · PMC6953105
23. Journal / agency Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S. Daratumumab in multiple myeloma. Cancer. July 2019. doi:10.1002/cncr.32065 · PMID 30951198
24. Journal / agency Franssen LE, Stege CA, Zweegman S, van de Donk NW, Nijhof IS. Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma. Journal of Clinical Medicine. April 2020. doi:10.3390/jcm9041195 · PMID 32331242 · PMC7230744
25. Other ASCO: Drug Shows Promise in Myeloma
26. Other Daratumumab Continues To Show Promise For Relapsed/Refractory Myeloma Patients (ASH 2012)
27. Journal / agency Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England Journal of Medicine. October 2016. doi:10.1056/NEJMoa1607751 · PMID 27705267
28. Journal / agency Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. The New England Journal of Medicine. August 2016. doi:10.1056/NEJMoa1606038 · PMID 27557302
29. Other Daratumumab Approved for Multiple Myeloma in US
30. Other Darzalex New FDA Drug Approval
31. Other Janssen's Single-Agent Darzalex (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM). 23 May 2016
32. Journal / agency Daratumumab (Darzalex). 9 February 2019
33. Journal / agency An overview of Darzalex and why it is authorised in the EU. 2018

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.